NAGE

Leading NAD+ healthy aging supplement reaches new health-conscious consumers at nearly 300 GNC and Sam’s Club locations across 44 states combined Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that Tru Niagen®, the number one healthy-aging NAD-boosting supplement in the United States†, is now available at GNC and Sam’s Club retail locations and online at www.gnc.com and www.samsclub.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260820988403/en/Tru Niagen is now available at nearly 300 GNC and Sam's Club

Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will present at the Midwest IDEAS Investor Conference on Thursday, August 27, 2026, at The InterContinental Chicago in Chicago, IL. IDEAS Conferences offer independent regional venues for top-tier companies to present their investment merits to instrumental audiences of investment professionals, offering investor-sponsored events created to benefit regional investment communities. Niagen Bioscience CFO, Ozan Pamir, will present on Thursday, August 27, from 2:40 - 3:15 PM CT in Presenting Room 2 and be

New e-commerce availability broadens consumer access to the leading healthy-aging NAD+ supplement in the United States Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States†, is now available at Walmart.com. The launch expands access to Tru Niagen through one of the country’s largest digital retail platforms, providing more consumers with a convenient way to purchase a clinically proven, science-backed NAD+ supplement to support cellular function and healthy aging. "Expanding Tru Niagen’s ava

10-Q - Niagen Bioscience, Inc. (0001386570) (Filer)

8-K - Niagen Bioscience, Inc. (0001386570) (Filer)

Launched pharmaceutical program targeting rare genetic diseases and aging related disorders in July Launched Niagen Plus telehealth platform Net sales of $29.8 million, including $24.2 million from Tru Niagen Generated $1.6 million of operating cash flow year-to-date Net income of $1.0 million and adjusted EBITDA of $3.0 million Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced operational updates and financial results for the second quarter of 2026. Second Quarter 2026 Financial and Business Highlights Total net sales of $29.8 million, including $24.2 million from Tru Niagen®. Direct to consumer sales on the Company’s website grew by 23% year-over-year. Gross margin o

Collaboration will support pharmacokinetic, pharmacodynamic, and bioanalytical studies for Niagen Bioscience’s lead investigational candidate for rare pediatric diseasesEvotec brings deep drug development expertise, serving leading pharmaceutical and biotechnology companies across the life sciences industryNiagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected Evotec (NASDAQ:EVO, Frankfurt Prime Standard: EVT)), a global life science company specializing in drug discovery and development, as a contract research organization to support the advancement of NB4168.

New epigenetic findings show Niagen NR reduces muscle biological aging and supports healthy muscle function Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the publication of a new peer-reviewed analysis of past clinical studies in Aging Cell examining the effects of Niagen® (patented nicotinamide riboside, NR) supplementation was associated with reduced muscle epigenetic age acceleration measured by the Muscle Epigenetic Age Test (MEAT) clock. In addition, changes in muscle mitochondrial DNA content correlated with changes in MEAT-derived epigenetic age acceleration, sugg

Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuity’s 46th Annual Growth Conference, taking place from August 11 to 13, 2026, in Boston. Mr. Fried is scheduled to participate in a fireside chat on Tuesday, August 11, at 2:00 p.m. Eastern Time (11:00 a.m. Pacific Time). To register for the Niagen Bioscience fireside chat webcast, please visit www.event.summitcast.com. Mr. Fried and Mr. Pamir will also hold one-on-one meetings with institutional investors

Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Tuesday, August 4, 2026, at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended June 30, 2026. The financial results will be reported in a press release after the close of regular stock market trading hours on Tuesday, August 4, 2026.Investor Conference Call:A live webcast will be held on Tuesday, August 4, 2026, at 4:30 p.m. Eastern Daylight Time (1:30 p.m. Pacific Daylight Time) to discuss Niagen Bioscience’s second quarter financial results and provide a gen

Scientific leader with deep expertise in NAD+ biology, aging research, and global research partnerships to lead the Company's expanding Niagen Research ProgramNiagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the appointment of Abhijit Kale, Ph.D., as Senior Director of Global External Research, effective July 20, 2026.Dr. Kale will lead Niagen Bioscience's Global Niagen Research Program, overseeing the Company's worldwide network of academic and clinical research collaborations while helping shape its scientific research strategy. In this role, he will work closely with leadin

Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR

424B5 - Niagen Bioscience, Inc. (0001386570) (Filer)

EFFECT - Niagen Bioscience, Inc. (0001386570) (Filer)

Virtual Q&A session to discuss the recently launched pharma program, the Company’s leadership in NAD+ science, and provide updates on Niagen Bioscience's business Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its CEO, Rob Fried, will participate in a virtual fireside chat hosted by KCSA Strategic Communications on Wednesday, July 15, 2026, at 8 am PDT. During the discussion, Mr. Fried will discuss the recently launched pharmaceutical program for rare genetic diseases and aging-related disorders, the Company's continued leadership in NAD+ science, and provide updat

4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

NB4168, a patented therapeutic candidate designed to have significantly increased bioavailability and a differentiated safety and pharmacokinetic profile compared to NRC, is the first investigational product to advance the Company's NAD+ platform into regulated drug development Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ science, today announced the formal launch of the first drug candidate of NAD Pharmaceuticals Corp., its wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases. The program will primarily focus on how NAD+, a coenzyme central to energy metabolism, DNA repair, mitochondrial function and cellular stres

8-K - Niagen Bioscience, Inc. (0001386570) (Filer)

S-3 - Niagen Bioscience, Inc. (0001386570) (Filer)

4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

4 - Niagen Bioscience, Inc. (0001386570) (Issuer)